Acrux Limited (AU:ACR)
ASX:ACR
ACR Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.03
Previous CloseN/A
Volume88.57K
Average Volume (3M)120.95K
Market Cap
AU$4.52M
Enterprise ValueAU$7.21M
Total Cash (Recent Filing)AU$863.00K
Total Debt (Recent Filing)AU$3.63M
Price to Earnings (P/E)9.3
Beta0.22
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding410,608,520
10 Day Avg. Volume76,863
30 Day Avg. Volume120,955
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Licensing / Royalty ModelAcrux's core model of licensing, royalties and milestone payments leverages partner commercial infrastructure, reducing the need for a large sales force and enabling scalable, high-margin revenue streams tied to partner product success. This model provides durable cash inflows if partners maintain launches and sales.
Recent Revenue GrowthSustained revenue acceleration in 2025 indicates progress in commercialization or milestone recognition from partners, strengthening the company's ability to convert R&D/IP into cash. If maintained, this trend supports reinvestment into development and reduces reliance on external financing over the medium term.
High Gross MarginA 100% gross margin reflects the structural economics of IP/licensing revenue where marginal cost is minimal. This indicates that incremental revenue translates directly to contribution margin, providing a durable profitability lever once fixed operating costs are controlled or reduced.
Bears Say
High LeverageA debt-to-equity ratio this elevated materially constrains financial flexibility, increasing refinancing and interest-rate risk. Over the coming months, high leverage could limit the company's ability to fund development milestones, react to partner delays, or absorb operating shortfalls without dilutive financing.
Negative Cash FlowsPersistent negative operating and free cash flows erode liquidity and shorten runway, forcing reliance on new financing or sporadic milestone receipts. Structurally weak cash generation undermines the company’s capacity to fund R&D, regulatory activities, or support commercialization without external capital.
Ongoing Losses / Negative ROEConsistent net losses and negative ROE indicate the company is not yet translating revenue into shareholder returns. Over a multi-month horizon, continued losses can deplete equity, restrict strategic options and make it harder to attract favorable partner deals or financing on non-dilutive terms.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$4.52M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 21, 2026 which is in 134 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 410,608,520 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-211.88%
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited (ACR) is a biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative drug delivery technologies and pharmaceutical products. The company operates primarily in the healthcare sector, focusing on transdermal delivery systems, which enable medications to be absorbed through the skin. Acrux's core products include various transdermal patches and formulations designed to improve patient adherence and therapeutic outcomes in areas such as hormone replacement therapy and pain management.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---